Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT06870240
A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury
Sponsor: Oragenics, Inc.
Conditions
Mild Traumatic Brain Injury, Concussion
Interventions
Neurosteroid enantiomer
Updated 1 time since 2025 Last updated: Mar 10, 2025 Started: Jun 1, 2025 Primary completion: Jan 1, 2026 Completion: Mar 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Mild Traumatic Brain Injury, Concussion and is currently actively recruiting participants. Oragenics, Inc. leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Oragenics, Inc.
Data source: Oragenics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .